CYTH

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.0164
Percentage change -2.65	%

Peers: SAVA AXSM ASND AVXL QURE FOLD INMB ANVS OLMA DSGN

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	42.74%	Shs Outstand	28.77M	Perf Week	-8.70%
Market Cap	17.34M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.50M	Perf Month	-15.13%
Income	-24.80M	PEG	-	EPS next Q	-	Inst Own	11.09%	Short Float	0.67%	Perf Quarter	-5.84%
Sales	0.87M	P/S	19.93	EPS this Y	-	Inst Trans	2.07%	Short Ratio	3.67	Perf Half Y	-52.92%
Book/sh	-0.47	P/B	-	EPS next Y	-	ROA	-457.10%	Short Interest	0.11M	Perf Year	-52.36%
Cash/sh	0.03	P/C	18.64	EPS next 5Y	-	ROE	-22663.91%	52W Range	0.59 - 2.12	Perf YTD	-62.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-88.22%	ROI	-	52W High	-71.51%	Beta	-0.50
Dividend TTM	-	Quick Ratio	0.16	Sales past 5Y	5.96%	Gross Margin	-302.69%	52W Low	1.35%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	0.17	EPS Y/Y TTM	46.35%	Oper. Margin	-2834.06%	RSI (14)	39.97	Volatility	6.93% 8.83%
Employees	8	Debt/Eq	-	Sales Y/Y TTM	-8.52%	Profit Margin	-2848.16%	Recom	3.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-4.31%	Payout	-	Rel Volume	0.56	Prev Close	0.62
Sales Surprise	-53.98%	EPS Surprise	-35.48%	Sales Q/Q	-52.82%	Earnings	Nov 12	Avg Volume	30.19K	Price	0.60
SMA20	-9.72%	SMA50	-15.73%	SMA200	-44.78%	Trades		Volume	16,898	Change	-2.65%

Today 07:00AM	Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Nov-14-24 08:05AM	Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -14.63%
Nov-06-24 07:14PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results (GlobeNewswire) +5.38%
Oct-21-24 08:00AM	Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer (GlobeNewswire)
Sep-05-24 09:05AM	Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) (Business Wire)
06:50AM	Loading…
Aug-22-24 06:50AM	Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement (GlobeNewswire) -26.98%
Aug-15-24 09:00AM	Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-29-24 09:05AM	Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office (Business Wire)
Jun-25-24 09:25AM	Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 (Business Wire)
Jun-14-24 04:01PM	Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results (GlobeNewswire)
May-30-24 09:00AM	Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1 (Business Wire)
May-16-24 08:05AM	Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
07:53AM	CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Mar-19-24 06:53AM	CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-18-24 09:05AM	Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (Business Wire)
09:34AM	Loading…
Mar-14-24 09:34AM	Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimers Disease (Business Wire)
Mar-13-24 05:04PM	Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Jan-29-24 09:15AM	Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimers Disease from the U.S. Patent and Trademark Office (Business Wire)
Dec-27-23 04:15PM	Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. (Business Wire) -7.87% -6.10%
Dec-18-23 09:15AM	Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol Cyclo Clinical Program for the Treatment of Niemann-Pick Disease Type C1 (Business Wire)
Dec-14-23 04:01PM	Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results (GlobeNewswire) +17.09%
Nov-21-23 08:05AM	Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium 2024 (Business Wire) -8.82%
Nov-15-23 08:05AM	Cyclo Therapeutics Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 04:01PM	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results (GlobeNewswire) +8.63%
Oct-23-23 08:05AM	Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million (Business Wire) +7.33%
Oct-05-23 08:05AM	Cyclo Therapeutics to Present at 8th Annual Dawson James Conference (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -5.00%
08:05AM	Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement (Business Wire)
Aug-15-23 08:05AM	Cyclo Therapeutics Reports Second Quarter 2023 Financial Results (Business Wire) -8.22%
Aug-02-23 08:16AM	Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc. (Business Wire)
01:32PM	Loading…
Jun-29-23 01:32PM	Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C1 (Business Wire) -9.77%
Jun-13-23 04:01PM	Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire) +18.56% -8.70%
Jun-12-23 08:05AM	Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo for Alzheimers Disease (Business Wire) +21.25%
Jun-05-23 08:05AM	Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement (Business Wire) +13.57%
May-15-23 08:05AM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (Business Wire) -12.39%
May-02-23 08:12AM	Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) (Business Wire) +15.97%
Apr-21-23 08:05AM	Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules (Business Wire) +7.53%
Mar-20-23 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results (Business Wire) -15.32%
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
08:05AM	Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements (Business Wire)
Jan-10-23 08:05AM	Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event (Business Wire)
Jan-09-23 08:05AM	Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo for the Treatment of Early Alzheimers Disease (Business Wire)
Jan-04-23 04:05PM	Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) +8.45% +12.34%
08:05AM	Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting (Business Wire)
Dec-30-22 08:00AM	Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire)
Nov-11-22 08:05AM	Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements (Business Wire)
Oct-18-22 08:05AM	Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C1 (NPC1) (Business Wire)
Oct-04-22 08:05AM	Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo for the Treatment of Early Alzheimers Disease (Business Wire) +7.92%
Sep-28-22 02:02PM	Cyclo Therapeutics Provides Business Update (Business Wire) +18.02%
Sep-07-22 08:05AM	Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (Business Wire) -7.71%
Aug-16-22 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-08-22 08:05AM	Cyclo Therapeutics to Present at the China NPC Association Meeting (Business Wire)
Jul-21-22 08:05AM	Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022 (Business Wire)
Jul-12-22 07:30AM	We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate (Simply Wall St.) -10.11%
Jul-11-22 08:05AM	Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022 (Business Wire) +7.39%
Jun-21-22 08:05AM	Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation (Business Wire)
May-18-22 08:00AM	Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
May-12-22 04:05PM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (Business Wire) +5.39%
May-09-22 08:05AM	Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event (Business Wire) -7.30%
Mar-29-22 08:35AM	Cyclo Therapeutics to Participate in the Virtual Investor Alzheimers Disease Spotlight Event (Business Wire)
Mar-24-22 08:05AM	Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo to Expand Pipeline (Business Wire)
Mar-23-22 08:25AM	Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (Business Wire)
Mar-14-22 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results (Business Wire) -11.75%
Mar-10-22 08:05AM	Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference (Business Wire)
Feb-08-22 08:05AM	Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo, at WORLDSymposium 2022 (Business Wire)
Feb-03-22 08:05AM	Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo in Niemann-Pick Disease Type C (Business Wire)
Jan-20-22 08:05AM	Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference (Business Wire)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Dec-16-21 06:16AM	Here's Why Cyclo Therapeutics (NASDAQ:CYTH) Must Use Its Cash Wisely (Simply Wall St.)
Dec-09-21 08:05AM	Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC Study Evaluating Trappsol® Cyclo for the Treatment of Niemann-Pick Disease (Business Wire)
Dec-06-21 08:05AM	Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo for the Treatment of Alzheimers Disease (Business Wire)
Nov-16-21 08:28PM	Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock (Business Wire) -20.16%
04:27PM	Cyclo Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire)
08:05AM	Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo in Phase 2 Study for Treatment of Alzheimers Disease (Business Wire)
Nov-15-21 04:20PM	Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results (Business Wire)
Nov-10-21 08:05AM	Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event (Business Wire)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
Nov-02-21 08:05AM	Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimers Disease Asset (Business Wire) +9.45%
Oct-19-21 09:15AM	Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment (Business Wire)
Oct-18-21 08:05AM	Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) (Business Wire)
Oct-06-21 08:05AM	Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab (Business Wire)
Sep-27-21 08:05AM	Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer (Business Wire) +6.23%
Sep-15-21 08:05AM	Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (Business Wire)
Sep-08-21 08:05AM	Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-17-21 08:05AM	Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results (Business Wire) +5.82%
Jul-30-21 08:05AM	Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo for the Treatment of Niemann-Pick Disease Type C1 (Business Wire)
Jul-27-21 08:05AM	Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo (Business Wire)
Jun-21-21 08:05AM	Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation (Business Wire)
Jun-19-21 03:37AM	Here's Why Some Shareholders May Not Be Too Generous With Cyclo Therapeutics, Inc.'s (NASDAQ:CYTH) CEO Compensation This Year (Simply Wall St.)
Jun-17-21 08:05AM	Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo in Niemann-Pick Type C1 (Business Wire)
Jun-15-21 08:05AM	Cyclo Therapeutics Announces Launch of New Website (Business Wire) -5.18%
Jun-14-21 08:05AM	Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index (Business Wire)
Jun-12-21 04:06AM	Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely? (Simply Wall St.)
Jun-09-21 08:05AM	Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference (Business Wire)
May-20-21 09:05AM	Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimers Disease Panel (Business Wire) +5.79%
May-17-21 09:05AM	Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results (Business Wire)
May-11-21 09:05AM	Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy (Business Wire)
Apr-27-21 09:05AM	Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo in Niemann-Pick Type C1 (Business Wire)
Apr-20-21 09:25AM	Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo in Alzheimers Disease (Business Wire) +6.69%
Mar-25-21 08:35AM	Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo in Rare Disease Niemann-Pick Type C1 (NPC1) (Business Wire) -17.88%

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyclo Therapeutics Inc

Upgrade your FINVIZ experience